Repligen to buy BioLife Solutions for USD 1.5 billion in cash-and-stock deal - RGEN News | RalliesRepligen to buy BioLife Solutions for USD 1.5 billion in cash-and-stock deal
R
RGEN• Repligen agrees to acquire BioLife Solutions
- Repligen agreed to acquire BioLife Solutions for an enterprise value of about USD 1.5 billion, paid 64% in stock and 36% in cash.
- BioLife holders are to receive USD 11.25 in cash plus 0.1442 Repligen shares per share, valued at USD 31.
- The deal implies a 24% premium to BioLife’s 90-day VWAP through July 21, 2026, with closing targeted for Q4 2026.
- Repligen expects at least USD 20 million of year-one synergies, rising to at least USD 30 million in year two.
- BioLife posted preliminary Q2 2026 revenue of USD 28.5 million, up 21% year over year.
MKDW
•
